[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1502587T3 - Formulering med vedvarende frigivelse af venlafaxinhydrochlorid - Google Patents

Formulering med vedvarende frigivelse af venlafaxinhydrochlorid

Info

Publication number
DK1502587T3
DK1502587T3 DK03386019T DK03386019T DK1502587T3 DK 1502587 T3 DK1502587 T3 DK 1502587T3 DK 03386019 T DK03386019 T DK 03386019T DK 03386019 T DK03386019 T DK 03386019T DK 1502587 T3 DK1502587 T3 DK 1502587T3
Authority
DK
Denmark
Prior art keywords
drug
sustained release
formulation
functional
drug substance
Prior art date
Application number
DK03386019T
Other languages
English (en)
Inventor
Evangelos Karavas
Konstantinos Lioumis
Stavros Politis
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Application granted granted Critical
Publication of DK1502587T3 publication Critical patent/DK1502587T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03386019T 2003-07-30 2003-07-30 Formulering med vedvarende frigivelse af venlafaxinhydrochlorid DK1502587T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03386019A EP1502587B1 (en) 2003-07-30 2003-07-30 Sustained release formulation for Venlafaxine hydrochloride

Publications (1)

Publication Number Publication Date
DK1502587T3 true DK1502587T3 (da) 2007-01-02

Family

ID=33522496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03386019T DK1502587T3 (da) 2003-07-30 2003-07-30 Formulering med vedvarende frigivelse af venlafaxinhydrochlorid

Country Status (15)

Country Link
US (2) US20060182797A1 (da)
EP (1) EP1502587B1 (da)
AT (1) ATE336988T1 (da)
AU (1) AU2004258732B2 (da)
BR (1) BRPI0412354A (da)
CA (1) CA2529393C (da)
CY (1) CY1107576T1 (da)
DE (1) DE60307819T2 (da)
DK (1) DK1502587T3 (da)
ES (1) ES2271514T3 (da)
PL (1) PL207998B1 (da)
PT (1) PT1502587E (da)
SI (1) SI1502587T1 (da)
WO (1) WO2005009414A1 (da)
ZA (1) ZA200600790B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CA2507685A1 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
EP1711169B1 (en) * 2004-02-04 2007-05-09 Alembic Limited Extended release coated minitablets of venlafaxine hydrochloride
WO2006136927A1 (en) * 2005-06-22 2006-12-28 Glenmark Pharmaceuticals Limited Extended release formulations comprising venlafaxine
EP1898886B1 (en) * 2005-07-01 2019-09-04 Rubicon Research Pvt Ltd. Novel sustained release dosage form
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
PL2010158T3 (pl) 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
WO2008140461A1 (en) * 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2211847A4 (en) * 2007-10-16 2013-10-02 Alphapharm Pty Ltd PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE
EP2403487A2 (en) * 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
WO2012170488A1 (en) * 2011-06-07 2012-12-13 Zx Pharma, Llc Multiparticulate s-adenosylmethionine compositions and related methods
CN103948557A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
ES2290027T3 (es) 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
BR0100334A (pt) 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
CA2444569C (en) * 2001-04-18 2011-01-04 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
WO2003013480A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US6696496B2 (en) * 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts

Also Published As

Publication number Publication date
ES2271514T3 (es) 2007-04-16
AU2004258732B2 (en) 2009-06-11
US20060182797A1 (en) 2006-08-17
BRPI0412354A (pt) 2006-09-05
CA2529393C (en) 2010-08-17
ATE336988T1 (de) 2006-09-15
CY1107576T1 (el) 2013-03-13
PT1502587E (pt) 2007-01-31
AU2004258732A1 (en) 2005-02-03
SI1502587T1 (sl) 2007-02-28
ZA200600790B (en) 2007-04-25
WO2005009414A1 (en) 2005-02-03
EP1502587A1 (en) 2005-02-02
PL207998B1 (pl) 2011-02-28
DE60307819T2 (de) 2007-10-04
CA2529393A1 (en) 2005-02-03
EP1502587B1 (en) 2006-08-23
PL379465A1 (pl) 2006-09-18
US20110171297A1 (en) 2011-07-14
DE60307819D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1107576T1 (el) Ταχεια αποδεσμευση των υδατοδιαλυτων φαρμακευτικων ουσιων
AP1748A (en) Chronotherapeutic dosage forms.
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
WO2004026262A3 (en) Abuse-resistant pharmaceutical compositions
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
MY148475A (en) Controlled release preparations comprising tramadol and topiramate
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
HUP0301887A2 (hu) Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz
JP2008543936A5 (da)
UY24288A1 (es) Procedimiento para la preparación de una composición de liberación retardada de paroxetina
HUP0003405A2 (hu) Szabályozott hatóanyag-leadású, szublingvális vagy bukkális adagolású gyógyszerkészítmények
WO2005027843A3 (en) Chronotherapeutic dosage forms
WO2007146293A3 (en) Improved composition and method for taste masking
NZ594618A (en) Transdermal pharmaceutical preparations
CA2453263A1 (en) Pharmaceutical compositions containing terbinafine and use thereof
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
ES2185452A1 (es) Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
WO2004052345A8 (en) Coating composition for taste masking coating and methods for their application and use
EP2397122A3 (en) Formulations of neramexane dosage forms
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
ATE535235T1 (de) Galanthamin-haltiges arzneimittel mit kontrollierter freisetzung